Preattack vaccination against anthrax may be cost-effective in certain populations.
Hopkins
Robert J
RJ
Waytes
Thomas A
TA
Zink
Thomas K
TK
D000881:Anthrax / Q000517:prevention & control*; D022122:Anthrax Vaccines / Q000191:economics* / Q000627:therapeutic use; D023482:Bioterrorism; D018890:Chemoprevention; D003362:Cost-Benefit Analysis; D006801:Humans
D022122:Anthrax Vaccines